Last updated on June 2019

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin


Brief description of study

Primary Objective:

To demonstrate the noninferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin

Secondary Objectives:

  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control
  • To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight
  • To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide

Detailed Study Description

Study duration per participant is approximately 65 weeks including an up to 3-week Screening Period, a 56-week Treatment Period and a 6-week safety Follow-up Period.

Clinical Study Identifier: NCT03684642

Find a site near you

Start Over

Investigational Site Number 8400039

New Windsor, NY United States
4.48miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.